Case 1:14-cv-01453-LPS Document 43-2 Filed 10/22/15 Page 1 of 17 PageID #: 260
`Case 1:14—cv—O1453—LPS Document 43-2 Filed 10/22/15 Page 1 of 17 Page|D #: 260
`
`
`
`EXHIBIT 5
`
`EXHIBIT 5
`
`
`
`

`
`Case 1:14-cv-01453-LPS Document 43-2 Filed 10/22/15 Page 2 of 17 PageID #: 261
`Case 1:14—cv—01453—LPS Document 4§_—2 Filed 10/22/15 Page 2 of 17 Page|D #: 261
`
`
`
`\J 7521 O0
`
`
`
`
`
`W. ...».
`'A's\I.‘_BA‘A'~\.‘AI:aA‘“L3 ~
`~v-- x-‘
`.:_;~s;»
`flag; .2.:§2§;‘§i rgie {=&‘:;§§’§€‘fis N
`
`
`»us\‘/\4\A.\.\\A!\'u\\\)\\\V,-
`§%§:§§§;«E.;§..
`
`
`
`‘Em’, Z13 ‘:§'I’A’E“;'c S §}}fLFAR.'f'.‘VE7£jN'"i‘ OF _‘,(_‘3‘.="~z/.'{1°w'il4_""R{_‘,§3_L‘
`
`
`
`United Sigma Paiem am! ”i‘z°;2a1°iem2:r'k Uffisrxe
` M.3w.§x QM, 2915
`
`
`
`THE E 'E‘(_‘§ (fi}:1R’E‘i}?“7k’ 'E‘H.A"i‘ A
`
`“.-D §H§i§i.§5‘L'.§"{} XS A TRUE CGFE’ FRGM
`
`
`
`'E"§iE REC{}i3E.i§S OF '§‘€f.{1S §_}§<“ic"EC. 3 0&3‘:
`
`
`KLS. PATET'~s'T:
`
`8,163_.62!?
`
`
`'§_?1-‘$313.’,-: Mm; 0}’, 265172
`
`E'_‘2‘%'<,‘,v
`
`
`
`
`
` By Ataéiierity of we
`Under S<.im:2~¢:t212a°§,' M" Cammarcas far ;(m‘,eEi.e<::tuai i’a'aperty
`
`anti Direcmr 91' the U:a1i<:ea;§ States Patent area‘? Tradmz;-ark Gffiaze
`
`
` (T§ert%fy>i::<g {_‘ii”f§cz:a*
`
`\-...................
`
`MED_DYM_00018026
`
`

`
`Case 1:14-cv-01453-LPS Document 43-2 Filed 10/22/15 Page 3 of 17 PageID #: 262
`Case 1:14-CV-01453-LPS Document 43-2 Filed 10/22/15 Page 3 O
`T
`17 Page|D #2 262
`11% §E§§§§§§ 111 $335 $151 §§j§E 3
`1&1
`$13? EEE; 11%? 31%
`E5
`
`(wt).
`
`‘$1111.117013 §T§€‘a;1‘“es
`1.31115 911111,
`
`2§3§§§'{’E§‘1:“§
`
`
`
`(.10; Fawn: “N11,:
`; 5) Bate of Fatent:
`
`
`US 8,158,520 .32
`May 1, 2012
`
`€3.33 ALi§.§£151°1Eé'§‘§I*e”§<l.&1§€1‘§3
`
`(54) &'.‘.'£)MB§.N A'1‘1’~i'1.?‘s‘
`~ ~
`-1,
`,~
`{*4 ‘i §~.§{€
`1?. is
`_
`.
`,
`.
`1m'e1.11ers: Anna? Lss11a_,Mum:>a1(1‘N;; Geena
`M:a1B.1:m'a, M111':1baé (EN)
`
`.
`,
`{/5}
`
`V
`'
`('7/3; Assiguee: s:1P:.A E.-§z11i?.e:i.1‘\41:11;5.11111(11\2'}
`_
`, ,,
`r
`,
`_
`,
`_
`,
`,
`,
`,
`,
`-,_
`'
`1\o£1a:-1::
`Saxbject :.-:1 an}; 6.1sc;1a11=_1er
`ienn of [1115
`pemznt
`emeiided or ’dd._:L3.'!:.'3d under 35
`U'_:‘C) - 5 v 331 ‘L, 98*," _. .1 ._
`\
`i /*1 ’ V
`' 33””
`..
`,
`3""*‘3?>a‘51‘~“
`Jun, 13, 21183
`
`.
`“’*3-“II”-N0-~'
`PC1‘ 11‘j1;;4j:
`
`.
`.
`(21.1
`122)
`
`-(am PC'T"N.r1.:
`§3'71 {CV1}?
`12>» 141
`
`13c'1‘;z;13e13,'112557
`
`J1=1~6».20115‘
`,
`_
`P151 1-°uh,No.: W003/105859
`PC'1‘1‘‘u1>~i>ai+:: 31391224. 1993
`Prior Publication Data
`
`US 2005/0025391 A1
`
`Feb. 2, 2005
`
`,_
`(8?)
`
`(65)
`
`(30)
`
`4.261.934 A
`4,263,289 A
`,
`.
`Z’§§Z”é§3 2
`4,310,466 A
`4,335,121 A
`4,377,575 A
`,
`,
`Q
`4,710,495 A
`4,351,755 A
`4,992,474 A
`4,994,439 A
`4,996,335 A
`5,063,222 A
`5,031,113 A
`5,164,194 A
`5,202,316 A
`5,232,919 A
`2
`5,420,120 A
`§’22§"§33 2
`5,658,919 A
`5,707,984 A
`5,837,699 A
`5,849,265 A
`5,889,015 A
`5,914,122 A
`
`4/1931 AlVareZ
`4/1981 Edwards
`V0
`31331 22?”;
`1/1982 Edwards
`6/1982 Phillipps et 31.
`3/1983 Stanh_e eta].
`c
`111
`ghzgggl.
`12/1987 Bodor
`g/1939 Mitsukllchj at ,,1_
`2/1991 Skidmore etal.
`2/1991 Longeneckeret al.
`2/1991 Bodor
`ll/1991 K ot
`tal.
`1/1992 C1.21I1r1lss1(1,e: etal.
`11/1992 Hettche
`4/1993 Claussner et a]
`8/1993 Scheflier et al.
`gltitctfllgeet 3,.
`5/1995 Boltralik
`31333 ii‘221?§,§¥Z1‘a
`s/1997 Ratnam etal.
`1/1998 Tjoengetal.
`11/1998 S
`'
`etal.
`12/1998 L1:?}3J<:Ireatetal.
`3/1999 Sequeiraet a1.
`6/I999 Otterbeck et al.
`
`(C°mm“°d)
`
`1-‘<1-reign Application Fricriijz Sham
`
`AU
`
`FOREIGN PATENT DOCUMENTS
`2003244799 B2
`12/2003
`
`51111. 14, 11002
`
`(GB) ................................. .. 021373913
`
`(Continued)
`
`'
`
`1'51)
`
`Int. ('31.
`\
`‘n-‘
`1'
`,
`(?'i.ME"m()
`Agflh :15/,1”)
`(:’m°‘m--’
`A"1K3Z’55
`(2.0i>6.f1'1)
`.45zz(31,-'55
`
`iflmé. H)
`Afifi. I /5,,
`'4 -
`,. ? ’/ '
`2;
`1,-E0‘)6'm)
`A 1‘é;_“1’58
`(4096-01)
`A5113 9/539
`(2006.01)
`A #511’ 3 7/03
`(2006.01)
`.~:1r5.iP2'.7/.1'4
`(.7.1'10(3.01','l
`31161? 1.!/3’???
`«'52) us. C1.
`..................................................... .. 514/171
`.n.
`I
`.
`'s:1e§ofZ'
`"‘,m'n.‘~§,- 2,
`514 Hz 71
`F1
`( lassm‘ Aha
`'Nmb ”
`(5 4)
`11_isIory.
`sspp1‘:—32at}o.11 file ‘E331 cornplefe‘: 5
`_
`Referesnces Citeei
`(50)
`
`
`
`U.S. PATENT DO€_‘,'E.='1\/1EN'1‘S
`233-754“ A
`4‘, No.5,”
`,
`.
`A
`~_ Ag;-,,~,11o 3:, 31.
`it 2.1.
`1/ 1971 V-‘ac-1'sr;l1oien ea 21},
`'
`2/1.1172.
`g/1973
`8/1974
`121,197!‘
`I
`5,1975
`ipps 1:121.
`.
`9/197:3
`a. C‘,
`.,
`11/1976 P321: ipps at 21.
`_
`:,1‘"-1‘5’f’--
`5.19,/m
`Edwards
`41' 1930 Alvarez
`9.149’-E50 Bede: at al.
`
`
`
`
`
`‘1
`
`.
`’ A
`A
`A
`' A
`, A
`A
`A
`.1,
`,,,
`3,939,686 A
`.,
`1.1.
`Z}
`4:, 37930 E A
`4,1z>;e,3>;z5 A
`-
`'
`‘ A
`
`A
`
`Q'1‘1iE.R 1-‘U ‘}LICAT1C“1\"'S
`;1re5ervafi‘ve. (r. 0‘ ) D-or13nd‘s B/iedicaj Dictionaxv "or 112111111 (,'<m~
`='umers "2111;-7)
`e- m1w1w 4 mm {mm *q-7w1ne41~s1«dicA1o~
`
`
`. 1”‘
`‘
`'
`"
`‘*
`1
`‘
`“
`“
`‘
`
`naIy,t11eftc.—'ed1c11onary~:o111
`e:'v::t:w~.."‘
`pxesezvati '9. (11.d.:) The A.me':1ca111 H1: ..ag:t® Medic,-:11 Dlctionasy,
`{2(2-07). Retrieved Nov.
`/-3, 3009 ‘E50111
`Imp:r':’r:se11icaJ—1li1=L1o:oary.
`‘s‘}1e‘1‘3*eedic1io11;a.7y.<;om/presem.Live.*
`p1'esr;~1'v-.1t'1Ve. (1111,) IX/102511)" 3 lvledical lliiciicnary, 3il1 e-.‘11'flo:3. (2009).
`Re1‘:1'ievef1
`'N'»:.~v.
`4,
`7215119
`,'L'1'om
`1111;::1’/medictai-gficti-cvnany.
`
`fhefieedictionazy.-:o111/pr~:ser1"
`*
`1’a*?=?>a5-’=1"==*i1iP:€0n11fl<i’15°11
`1*1>M1'~-'i1‘W! 011441111115
`.
`.. .
`.
`.
`..
`_
`Beilaeszia, ME). 113: 21100 Ponmann I) :11 211: Ac~:r:ptab1'liz'y of legal
`tr-:zu11en’i. of ahexgsc 1111111118 1111*}:
`'1
`11::
`1,-1a:‘1on of a cortxcm-.1
`
`(bmgi.
`,5)
`V ,\M_1m.,M)‘ W, -,2 ‘$13,,’ 4,
`2099, pp. 2:73.279.
`
`(Continued)
`.
`Primary Exammer — Johann 1?.1chte1'
`Assistant Examiner — Thor Nlelsen
`(74) Attorney, Agent, orFirm — Conley Rose, P.C.; Rodney
`B" Carrol]
`_
`(57)
`AESTRAC"{
`
`-
`-
`~
`-
`A pharn1ace11t1cal product or fonnulatxon, wh1ch compnses
`azelastmev or a pharznaceuncally ‘acceptable salt, solvate or
`phys1o1og1ca1lyfunct1onal derrvauvethereof, anda stero1d, or
`_
`_
`,
`V
`apharmaceutically acceptable salt, solvate orphysiologically
`-
`«
`~
`«
`«
`funchona] der1vat1ve thereof, preferably the product or for-
`mulauon belng 1n a form smtable for nasal or ocular adm1n—
`1S1r3T10I1-
`
`43 Claims, No "Drawings
`
`ac......
`
`. ...~.~¢.w4-.».~.~v-.e1-2-1-av-.w.:.w.~.................................................».r.~.».ww.-~w.~..w.,.~.. . .._..,.,,.,,,.,.,.,._ , ,
`Gnpy pmvzzsedm 115311113 1mm me PER?» image 1;a1a1s"".§§e nn 113/54/2915
`
`
`
`
`1A(I11-1:. N»-rm-v~rvv~nrnrrn\Vh\'.'.'.\'.'r.'.'xt.'v
`
`MED_DYM_00018027
`
`

`
`Case 1:14-cv-01453-LPS Document 43-2 Filed 10/22/15 Page 4 of 17 PageID #: 263
`Case 1:14—cv—01453—LPS Document 43-2 Filed 10/22/15 Page 4 of 17 Page|D #: 263
`
`3&2
`
`MS §§,3€§§§9€§3€}
`
`2
`
`
`
`‘U-IS. ?,~’(I'BNT I3(}C1.H\/II3.NTS
`
`IE’
`
`S§2§U)73
`
`620 A
`10/1999 3.;-was
`>1!
`/firm
`‘
`A
`1 1./1999
`
`‘‘°._3 '°*
`
`—
`v—
`-
`°W°4°
`
`5,
`*'
`5,
`
`6?
`
`5°
`5 ‘
`5
`6°
`5 ‘
`H .
`-~
`-
`
`,
`~
`
`
`
`
`
`
`.
`,
`514,503
`
`37°.
`
`we
`we
`we
`we
`we
`W0
`we
`W0
`we
`wo
`W0
`v.{o
`we
`we
`we
`W0
`.‘—”f”
`9,0
`9,0
`“,0
`35,0
`-‘)3?
`92“)
`V30
`“,0
`W)
`W0
`W0
`W0
`V“
`W39
`W0
`"*7?
`‘W
`W0
`W0
`W9
`‘W
`W0
`W?
`"W
`‘W
`W0
`W‘?
`W0
`W0
`we
`we
`7'?“
`we
`W0
`'\.W_‘:
`we
`W0
`we
`
`
`
`
`
`
`2"”7-“‘:‘5:’i’35
`—’
`-
`»~
`9104252
`9214472
`9531954
`96195.99
`
`953 .5
`9'7o133:7
`9705136
`9m;z92a
`we. 1 721
`97'.z17;>.4
`9724355
`974cm
`9746343 AE
`9817676
`9334595
`gmm
`99§1'§§'.7
`5/1999
`99r"§".”?
`@399
`993*“?
`3‘.{':"‘3’°
`"“‘“‘3.’.?
`f”"}fi900
`@0338”
`/’,*;?’°0
`GC'33§1$
`8' Em
`0mm.’
`O
`OC"‘99.?':‘
`11/3"“?
`09653“
`1”"?
`C.‘:9‘”.1g
`3
`1
`9:693-*1
`
`3
`3
`6334331
`""f”"
`‘3:3’3,"‘:3’§
`’i",’"‘?”.”1
`9‘f'3’9*”’
`3.1.9531
`”ff52.".7:2
`jg/‘O0;
`0"'7>?""6
`W?0"1
`W332’-*9
`"3
`3'71
`‘”~’3”“
`1'3/‘Z001
`0373745
`1/2001
`07-00199
`1’?300?~
`0200579
`1"?-9'-'32
`0203555
`02‘>‘7’76‘7
`1/2002
`1/2001
`
`_
`-
`J.
`.
`~
`023412205
`2/2'
`2
`02i32?68
`2/2002;?
`0226733
`4/2002
`0236“
`V20-712
`03<>5M22
`‘7/2002
`()2055i8(>
`7/2.002
`-32966 22
`moo:
`037"“-’-"’
`’”-’?3'72
`ozweess
`m/2002
`].0/1130:’.
`11./2002
`12/2032
`1/2003
`2./3003
`
`{)2-C)88‘;67
`ozwc-$7.9
`<»3:<x>«>:241
`33:21:42.‘:
`
`&.’87‘532
`.
`s,921;757
`7.;o1..ae5 132
`7.;244.74;>. B2
`7.77<».3x_s
`:2
`2002/’00(~.12z1 A}.
`2m2.,='oa7r«,32:z Al
`;znn;2/cnzxzas A1
`7.002/C-1G3392 AL
`2002/0165211 A1
`Z($0?,/G173-19-6 Al
`2002/0177531 Ai
`290::/c-$12019 A1
`2(I-{>3/C-073676 Al
`2003,/c-109511 A1
`2003/C-144257 A1
`
`1&3 A1
`2004/easzanz;
`./-U
`2004/c-:3¢:.91s A}.
`2m4/o2r:43§.>9 A!
`2004./'o235sa)7 A1
`;=.n<ws,ro;.142s32 A!
`' 20:25/0163724 ./u
`2005/(219225: A!
`21205,/015033; A1
`EH06/O2383(?6 A1
`2007/0020330 A1
`2!)-T)9!'02S67rS2 A1
`29-390291.124; A1
`2O(>9/O31839'7’ Al
`gum/ms21A.7 A}
`
`-
`
`
`
`’
`4
`E'pi'm;3x_fl:c':2et;1L
`:>;;7;°§e;eta1.
`Pairetetai,
`Os‘-raakken -at a1.
`Kapian eta}.
`‘W-;-vzvife ital.
`
`
`
`.
`8/2003
`11/2r_>o2
`11/mg
`11/zoo:
`/2003
`4/2903
`.
`-
`a/2903
`7/2093 Biggad:k<:e.r.a§.
`#2003 C::::::o1:dc‘,r.a3..
`3/2904 K.r;;..:1r;r.r:r:\t2.l.
`7/20¢-4 Gaxxeitetal.
`-
`I-+11.
`'wei;mc.1; at.
`"Y’;-zmietal.
`I*.»'§1y:adaiar.a3.
`Jost..:>r=c.e
`_.
`5/guos D:mg.a;*.La1.
`
`10/2o«>rs Lane
`/2007 Danget :11.
`11/2065:
`11/;z<>c>.9
`12/2<m9
`5/2m.c-
`
`
`
`'
`l7‘0REI<3-N PAT:-:NT DOCUMENTS
`s;s9s:e.';z A.
`11/1921
`m55,5,0_5
`M959
`4/~00}
`_‘
`09
`10/1979
`5:/1932
`
`gggggggggg A;
`3836 '79 A!
`onoczo"/3
`(»<>::7'4o1
`
`DE
`DE
`
`E?
`E?
`
`E
`5?
`
`EP
`51>
`GB
`GB
`GB
`(,3
`(38
`(:3
`GB
`GB,
`-133
`IL
`JP
`JP
`
`42/2003
`.0-: 7
`
`:-~ ~,
`rs
`5/2003
`‘i’-£332
`71;’ t’
`".:'G”3
`g’.‘C'”3‘
`3/2003
`./2:293
`9/2003
`24>/200:3
`1?./.3003
`2./2004
`3/20:34
`z/20022.
`4193-;
`
`
`
`03033000
`uaorsnsezs
`ozmoggg
`".
`""’ ',
`034:4
`
`W»; 0
`”'t""“'*'5’
`(’§"{?4.“T‘§
`of-abeagsg
`()1-(£66036
`
`'55
`93
`397 93
`n3oza<sis99
`033.0'3i<5G A1
`Z(}04s')l3l5fi
`' A1
`
`2003112333 A2
`8723219
`
`WO
`VS?!)
`we
`"
`W0
`
`{,,,0
`2,
`F30
`we
`wp
`‘W
`""0
`"M;
`WC
`KW):
`
`WO
`23%.
`
`=i:’195€6
`1r./::99c-
`3/199:.
`Mi,
`: $533;
`4/2'.BC'9
`6i20C-9
`3.'1s>7c-
`1149?:
`my
`M9 ;
`7/2973
`2/392:2
`5/393)
`i2/i934
`ggygoog
`:2/1!;-9.
`7/2.->2;-2
`ii/1996
`
`
`
`m:'9ss;;
`039:<asx
`(251595:
`\1
`A.
`f;,r_f<8%§§
`1541973:
`;:<v1'2o.<.:: Al
`11919.55
`296453
`BS4372
`1438940
`1517273
`2079755
`2033
`{)
`2149
`233953; A
`109656
`04293257
`2291072
`
`»
`
`
`
`
`
`,.,,..—..-v.-w.~«».~».-».«~».~«-v.»-.~.v.......
`
`
`.......«.-5-...«-.....\....x..\......,..«...,........~......
`4
`
`K ... .
`
`.
`
`..._.,........._...
`
`
`on 93“)4i2é.i.éq....w~w.,m~,.......v...v.....mufi.............i....22.NK2..,‘.,....‘.._m._.A.m.u
`
`MED_DYM_00018028
`
`

`
`Case 1:14-cv-01453-LPS Document 43-2 Filed 10/22/15 Page 5 of 17 PageID #: 264
`Case 1:14—cv—01453—LPS Document 43-2 Filed 10/22/15 Page 5 of 17 Page|D #: 264
`
`
`
`US ?;§3,.§.{§?$,.€ii23.{§
`}.’.a-3;: '3
`
`OTHER Pl.l'BLlCATl()NS
`Bus-so W ‘Iv’ el 31.’ “C-3rtico5ter'oid—Sparing Effect ofrkzelastine in the
`lv.Eana1gen1enf. ol'Broz;r;hial As€:~..vna”——-—American Journal of R(>:¥pi1‘a-
`rory and (_‘.1*i?ical Care Medicine, American Lwxg Association, new
`York, }~Wv', vol. 153, No. 1. 15996, pp. 122~l’.72,p.
`l27.,c~.‘.-E. l.pa.1'a-
`g,-aph 2.
`l11tamaLion5.l Search Report 1mderSe»:i'\ou 17 UK l’a1enL0Ef1-:e cola
`locniotas, including GB, El’, W0 8: US patent, specifications.
`l:C'I€l;_1._T1 coxiuuunicafirm from the yriority applicati-run--»—Intex'r:axiun;s.l
`Search Report, P(_T’l'/’€rBG3/02557, sep. 17, 2003,31 pages.
`Foreign commtufication fr~:«a:1 the priority application-—~Interz::a:ion:J.
`Pre‘: iminary Examination Report, }’CT/GBC-3/C-255 7, Aug. 26-, 2094,
`6 pages.
`Foreign coriuuurilcailmr from 2. related counterpart applies
`Exzsxijnaiiou Report, E? Appliuatiorx 0373828-3.1. Nov. E0, 2065, 4
`pages.
`Foreign co:xuuuni.c::tl<m from a relared cuunierpart a'_r:pli-:ar.io.u——
`lb(zn;i::.ario:: lrlcgsorl, El’ Application L-3’/38280.1” Jul. l3, 2007, 5
`pages.
`y
`Applicants response te foreign cozxtmmricaiion»-»-E? 037382801
`May 22, 2()(,‘6, 36 pages.
`Appiicarzts msponscz to foreign conn11ur:i<:.':?l£m.—‘f5P (l3738380.l,
`Jan. 18, 2(."U8, 17'
`May, Percy. at 9.1., “Mars fjlucsmistry of Syntheti-: E)rugs,” Fifi};
`Eziiiirsn,
`.1964,
`E2--1'7, Loltgmwus.
`AB?! Compesrdium of [Base hllteets and Surryrryarixzs ol{Pro4lu<;t Char-v
`acieristics,
`l"99.‘¥—I‘.()()0, Cover page, p. 43 and Iridex p.
`l882,
`Dalaplzami Publications l',i:ni.1e1l, I..c.m.-iris, Great Britain.
`Dykewirsz, Mar}: 3., at al, “l)iagz1osis md Mmragemer-.t of Rlaiuitis:
`flrmlplete Guidelines of the Joi.-:.t Task Force on Practice Parameters
`in Alle.1;._>.j. Aszlum and krrmimoiogy.” Annals 0fAIlc*.1'gy, Asfhrnz, &
`lmmzinoiogvv, vol. 8 l , November (Part II) i998. pp. 478-518.
`Foreign conuraruiczfion fiom 2 telzazexl cothjteipatt appiicizticn-.
`Notice ofOppositio;r., '§:'.l-’ Appiicarion 03733236. 1, £‘e1::.22, ‘.20 10, 27.
`pages.
`Office Aciirm dated Sep. 30, 2010, LES. Appi. No. 12/508,338, filed
`312}. 23. 3.009. 2.7. pages.
`‘
`Office Action slated Say. 30, 2010, US. Appl. No. 12/508,393. filed
`Jul. 23, 2009, 31 pages.
`‘t’>5.l.e.rii' applic:zLi-an s-milled “'ComJai.ua'Lio.1: r)f71‘::c‘.i3.<;l'ir:e and s£eroini<;,*"
`by Am»: Zulla, er al., filed Sep.
`10., 20 is’) as U. Appl. No.
`E2/i~i7.‘.4‘,7§ I
`Hodges, .~‘~Jom;;an. at 2.1., “Antimi-:r=;-3:93-1: Preservafive Eificacy 'l'r.:sr.-
`Eng,” Hamil:-ook of Evil-:mbxologlca.l Quality Cmzttoi, Pl1a.'maceuti~
`<::2=< and Medical Devices, 2060, p. 363 plus cover page and pnbli~
`cation page, Rrsslunamci M. Baird, of 21., Ezlafor, T2,}-"lo: & Francis
`Publish-or. USA eJ.\\r_i Canada.
`
`rm.’-ilations: An
`Hen‘-arc», ‘Jarircil. 11., “?reserva.ti.ves in Ophthalrnic
`Owsrview,” Arrzla. Soc. Esp. Ufifllflfil, 2697. vol. 82., pp. 531-532.
`Johnson, i‘~/lalcczn, "Develc.-pzrrlrzm ofiiu Licasoue propionaie andcomm
`parison with rlihcsr
`inhaled aortic-3-steroids.” J. Allergy -‘«‘.‘.lin.
`lmmunol, Apr. 1998. "vol. 101. No. 4, Pan 2, pp. 3434-5439.
`Foreign comnilinicatirm from :1 reialezl counterpart applicati~t:n--—-
`CA2,489.427. Ex;-.m1'_natlor1 Report. jun. 18., 2010. 3 pages.
`Foreign -:8-rrrmnni¢.3.f.i-‘J13 from a relarerl counterpart applic-.aIlen—
`CA2,489,42'7, Examirmtion Report, Mar. 2-1, .2011, 2 pages.
`Foreign cmzuuurvication from 3 rciaierl 4.-ounlerp:m' appli<:alion—~——
`Examinafion Repair. EP Applicarlorz 037382SD. l, Nov EC‘, .1005, 4
`pages.
`Foreign corrmnunication from 2: Ieiatei counterpart zzpplix:ati<;n—-
`Exarrsination Report, El’ Applicafirin O3738280.l, Jul. 18. 2013’/', 5
`pages.
`Foreign COIla'J’:i11l1iC.iifi0_13 from a reizited counterpart s1pplica.li<m-—-
`Notice ofl_ule_n£ to Grant, E? Application O3‘73823(}. 1 , Oct. 23, ‘.1068,
`6 pages.
`Eotelyi communioati-:-n fmrn a rolairad crsunterpzrt ap}:e1ication----
`Al.lZ(‘rG3L-144799, Exami.1m:‘irm. Repcgrl, Nov. 20, 2007‘. 2 pages.
`Ersreigzl corrara’.-unicaiion from :2 rclaiezi counterpart application-——E~I.R
`Iii-~2-I)-‘.)4~'.7f.l2075l9, Examinaiion Repoit. Aug. 26, 2010. 8 pages.
`Ger-.r:aro,A1fon::o 1%., ed, at a.‘:., Remington: The Science and Pracrice
`ofPh8Z"I£l21(:V 7000, 205:1 edition, vol. 1, pp. 785, 830, 831 plus cover
`page 25.31‘; pa,—:mca:ioz1 page, Lippincott Williams Willdr-.s.
`
`“PreseI1.I.atior; of phaimacetztical products,"
`Gilberi, Perer, er
`Encyclopeefia ofE"imm12.ceutical ’lecl1nolog,y, 209“ end ediilou, vol.
`3, g:-. 'Z2’ii~i plan, cover page and publicazion page, Marcel l'3:‘.A.<(:.'. Inc.
`Oifice Ac1io11(FEnal)d;U.ed Feb. 18, 20) 1 {L13 pages), U. S. App}. No.
`
`l2./598,388. filed Jul. 23, 20 "51
`Ofiice Action (Final) dated Feb. 24, 2011 (20 pages). US. Appl. No.
`l2,’501§.,”§9‘3, filer}. Jul. 33, 2009.
`
`
`~
`Indra K, e-13.,
`ulm‘ ’I'l3er'apeuli.cs and Drug, Delivery: A
`rsciplixrary App:‘o:a.<:}5, I 995, pp. 381--38$ plus cover ‘p:1g.e and
`publicafion pzige, 'l‘ec§r:nc-min: Publishing Company",
`
`zspplicationu-—
`Foreigrs commuraic ion from a related -zouxitmpm.
`Summons to Attend Oznj Froce-:-dings. El’ Application 0'3 ?’;‘58'.Z 80. l ,
`Feb. 8, 26311, 1 page.
`Foreign corxurimiicatiwx frorr a related -zounterpari 3ppll,¢;alinn-~-
`"3-.auninar.ion Report, RU 2005100781. Apr. 3.3, ?(‘:t')’7, 6 pages.
`Foreigrx cozmmtlnication from a ‘er;-lateri <:o11ntezp;:;“i applicafionw
`Examirratiofi Report, RU 2003100781, May 23, 2008, 3 pages.
`Pf?-C)E‘£LTLlC 0'ppGSifiDI!. lmiizm Pr:‘;en1.Appiica?'-3n 20.92/lC.Ql.NP/2007
`sié>.tc<i .‘.-':2n. 8, 2097, 183 pages.
`MaNeely. Wendy, e-1:11.. "lntranrrsal Azelasrfme A Rcvievz of its
`easy in the ivlarazzganaerzt ofAllergic RJ1'u1itis,” Dr-.ags, 1998, vol. 56,
`No. L pp. 914.14.
`ABPI Data. Sheet Cc:-;n3perrdiu111, 199596, cover page plus pp. 38~3.'*J,
`l)a1;z;.pliars11 Puhlicafions Limited, l..o1uio.u., Great Britain.
`Aurora, Jzxek, “Nasal Delivery; Developrrient of'Na.s;~.l l}:‘.liV£:ry Sys-
`tems: A Review.” Dmg Delivery Technology. vol. 2. No. 7, Oct. 2002,
`8 pages, llftp://W‘.>,'w.d3ug(li:iiV‘c‘Jl eel:.com/MEI/Segmen':s/Puhllca-
`tions: Ar§*Zs:le&id=9l3B i9EE2l‘2.‘a'F4620Sf9C‘:Z0$l4 73l75l73CA.
`Block, 303351 H., et al, “l11or,_-zauic Medk.-inal and Phzmnaceutical
`(lhver.-':i:::1y," 1986. cover. publication, and prefao-2 pages plus 5:. 1-3-1),
`Indian .F;ciitio.u, 'v’a:g.l;
`9 Publishing House, B-.".-mbay, lr.\r.i.i2..
`
`Cipia Sizsfy-»Nintlrr nual l~’.epor:‘ 2€l(‘a4~2005. c. ‘er pages, 'mforma-
`{ion prrgcs. pin.-s pp. 3, 5, and 443.
`fismxirs, Michel A., at 51., “Adding lsoramdinc to Topical Nasal Stem
`wirf. Therapy lniproves Moderately Severe Seasmxal Allergic
`
`Rlrinocctnjurrciivill rs.” A.<ivznces in Therapy, vol. 22, No. 6, N L>v./Dec.
`1995, pp. 3-‘E0-v349, Eleairlt Comm":
`avjoas Inc.
`Foreign communication from at I alad euuntszrpart application-~
`‘lmrrslaiim of 03365 Action, Israel Parent Applica.U'.o;.a 16577 1, Jul.
`11, 201.1, 3 pages.
`in ‘:’~\\.rrrx1s‘::a.te<l
`Hodges. N. A., at al., “}".rescrva1ive liificacy ’l'es€::
`Nasal. Products: Reproducibility and .F2.r:':‘4>rs Afi‘ecL'u1g Preservafixre
`A<::‘ivi‘ly,” J. Plzann. Pluanuac-.31., 1996, vol. £8, 52;}.
`l23’.7~l.242.
`App1ic:mr.=;
`response to foreign co11\r1111:1i<..::*§rm——l.<.l2.E0-3004-
`
`’.7(3Z0S19, Dec. 27, 20.10. 18 p
`.
`Prewribing Enfonuarior; for Asicpr<ve®. Nov. 2010. 20 pages. It/Eeda
`Pllarmaceuticals Inc., Scvmerset, N), US.
`‘wcscrllrlng information for Rhinoccrt Aqua T”, Dam 2010, 3» 2 pages,
`Astrakferieca LI’. Wil:.ui.2;gr.ozz, DE, US.
`1’ -:-duct lnfornaztiors. Na.<.om‘.x.®, Aug. 2061, 22 pages, Sclmrirrg
`Corgsoraxian, Keriilwortli, NJ, US.
`Safety 13am Sheer, SDS No. 1 10556. Jul. 4. 2003, V E 4, Flryrlase Nasal
`Spray, 5 pages, Glaxufimithliline.
`Safety Data Sheet, SDS No. 110535, Jun. 23, 2008, "V13, Be~:o.ua.'=e
`l-layfever Allergy Spra ', 5 pages. Giax0Sm_i1_hK.line:.
`Wlsezmn. l.)2.r1d:.a R. :31 al.,
`'111_Lr:mas::l Flut:'c2.sone Pro;,»i.oz1a1‘e: A
`Re:3§pz.'fi::2.l of its Phzjmacnlogy and CE’ "cal Efficacy
`the Treah
`merit of Rh'mit:'::,” Drugs. 15.3597. vol. 53, I‘~3.-:-. 5, pp. 835307, Adis
`Inlemzazional Limited.
`I
`World Review 2005: The Flu-_rrn:«,ceutlc.r-.§ Marlcczt. vol.
`Iional, lms 1-lealE}:. 2003 , cover, preface, and »:op)'rig.ht pagas pl1:5 pp.
`4-42 and 5»: tl*:r«':ug,h 5~l 1, IMS AG.
`Oppositi»:-n to El’ 1518731. Aug. 8, 2011. 19 pzages.
`Barge. Slephera M., at al., “Plrar111acoufi:;3l Salts,” Journal of l’har--
`mmteaatical Sciences, vol. 66, No. 1. Jan. E.‘77. pp. 149.
`AVlv.‘.€l® RC./Cl... Micz'ccrysEalE5_rze Cellulose and (‘.zrbox},'1\\er§Jylcel—
`
`lzal-use Sfydlllfrr, NF Disrper
`2 Cellulose. BF. Specifications and
`Analyfical Methods, Rll-E5 .-pdarerl O-ca. 1995 (Feb. 1999). 6 pages,
`FMC Biolh-lymer.
`Baena-Cagnani, Carla-3 E ., “Safety and Tulerability cfTr<:=atments for
`Allergic ll}-.i1=_itisin Children.“ Drug S.1fety.2’.(}(';4, vol. 27. No. 12. pp.
`833398, ADES Dara. Inlonnation BV.
`
` \-«\-p.\-ww».»ux.mMu...~w.w.-...-.-.«..-.~
`s~..................... ..
`
`.....u---x-qe<<<<m«-z-:~<~<~e<~<~z~a-me“-.~».,.............~.—.~..-s,,,,,,,,.»..~».»....~,~.-.».o.-as-a-svs-:-.-an-s-w.~.-w... . .. . ..
`.... N.
`.
`Copy provide by memo rr2?n“"?€§§§é‘ararze smaéfiazabase on 03/‘G-’-3.r’2l3i5
`
`-~--n-’-‘-<---’w-
`
`ii:eu-.-.._._.,.»-in-rKe.,.....ex.s.A; (((r.»..».v;
`
`
`
`MED_DYM_00018029
`
`

`
`Case 1:14-cv-01453-LPS Document 43-2 Filed 10/22/15 Page 6 of 17 PageID #: 265
`Case l:14—cv-O1453—LPS Document 43-2 Filed 10/22/15 Page 6 of 17 Page|D #: 265
`
`1.15% 8,l6?§,€372El 132
` r
`.,e
`F‘
`
`
`
`
`
`“Pl 519731, 201 3'.
`C191. A’s resp its»: to Sratcrrscmt o.l'0pposition fr:
`
`S -.
`‘id, “Fixed drug corrrbinatiw‘-cs: w‘ ‘vi ones can be recom-
`
`
`mf tie
`"(i’.0rrent'l'herapea1ti<
`();:-it-oi1er}t’s Staterricnt of -Dppi
`Result of oral j'JF“\K:f1€2iling.$ dated
`M19731.
`
`
`
`
`
`
`
`
`
`2 sut3m' siorl dated Sep. 23. 2011 regaiiling. list.-r;i.‘;:é'1c::-.i'l~
`13-ppon-<::1
`dings on l3l’P‘arer1t.l‘>'«.'-.":. 1519731.
`we at oral pr»:
`'(>ppor1erit‘s .'- mission iiiltfid Sep. 23, 2013. regarding aildirl»:-nal
`documents on 1
`i"?l‘lI~‘2}.lI No. 1519731..
`l‘:5.te11tee’s iilllizlltlsfiitlll
`rlatmi Sop. 19, 2013 on 13:17‘ Pateitt No.
`1 5 1973 l .
`Pa.te:1tl‘v'o. 1.519731.
`I-‘ateuteek res;g:_:1a.=;e of Sep. 6, 3010 of
`Hampel, Frank C, it al., l')ouble~l;l.i.1ar.i, plac
`.
`_
`-ollerl si"ri'
`
`
`
`
`e,
`autelasijne an-:1 iluticar no
`a
`gle nasal pray
`ivory fl
`
`Annals -:.-f Allergy, Asthma. 3: Lrr«_
`.-gy,/\.t1g. 2010, ml. 105. pp.
`168») 773.
`“i"l‘:'iti<;asono firroatei’
`to tire "Stiller,
`Big.g.arlil<.e. Keith, Letter‘
`iluticasone pr0pioua.te-~-~riif‘fe:mt drugs with different 3_.1mp.~:;1ies,”
`The Clinical Resp.-i1'e1tory.lou=.m;l, 3011, pp. 15$?--125/3.
`fiuticasone
`Rapid
`mse tport‘. summary with critical app1ta.i..=;a
`
`_hanitis: a
`tefo1'se:tsorial allerp
`review of the cliitical am r;os:.-tifectivcness,
`jun. 13, 201 1,
`Fiiiticasorie 1*‘urea?-2 for
`ortal Allergic Rliinitis.
`Oilice .9xer.io.nti;1ted Sep. 9,
`..-ll of 11.3. A9313. No. l it/50=§<,3>?8 tiled
`Jul. .23, 2009.
`Of
`“tin-‘:1 dated Sep. 15, 2011 ¢:<t”U'.S.Ap;:l. L-‘~10. 12/'.‘30S,3§?3 filed
`009.
`
`'
`
` . 1, 2011---.206. .«. ll’...
`
`(1 Aug. 31, 2010 {:3 pages}, 1} Appl.
`‘:10.
`.
`l'_71e’3‘7~‘l,523 file-£101: Inn. 21, I’0l}‘9.
`Appliczutts’ respaxise slated Oct. 5, 2010 (8 pages’) in US. Appi. Mo.
`1.2’./3’74,523 {livid on L-‘an. 17.1,
`
`
`
`
`
`' 1, (20-10121111 (2; pages) in 15.21.
`‘(L
`212119.
`2011 (S pagzzs), US. Appl. 1'10.
`
`
`
`9.
`2, 2011 (9 1;-ages) in 117.531. Appl. No.
`
`
`
`
`
`Galant, Stanley P., et al., “Clinical Prescribing of Allergic Rhinitis
`Medication in the Preschool a.ndYoung School-Age Child, What are
`the Options?," BioDrugs200l, vol. 15, No. 7, pp. 453-463, ADIS
`International Ltd.
`Wang, De-Yun, “Treatment ofAllergic Rhinitis: H1-Antihistamines
`
`and Intranasal Steroids,” Current Drug Targets—.lr2t1:s.
`stion &
`Allergy, 2002, vol. I, pp. 215-220, Bentham Science Publishers Ltd.
`Meltzer, Eli 0., “Allergic rhinitis: Managing the pediatric spectrum,”
`Allergy and Asthma Proceedings, Jan.-Feb. 2006, vol. 27, No. 1, pp.
`2-8, Oceanside Publications, Inc., USA.
`Ratner, Paul H., et al., “Combination therapy with azelastine hydro-
`chloride nasal spray and fluticasone propionate nasal spray in the
`treatment of patients with seasonal allergic rhinitis,” Annals of
`Allergy, Asthma & Immunology, Jan. 2008, vol. 100, Cover page,
`publishing page, pp. 74-81.
`Ratner, Paul I-1., et al., “A Comparison ofthe Efiicacy of Fluticasone
`Propionate Aqueous Nasal Spray and Loratadine, Alone and in Com-
`bination, for the Treatment of Seasonal Allergic Rhinitis,” The Jour-
`ml of Family Practice, Aug. 1998, vol. 47, No. 2, pp. 118-125,
`Appleton & Lange.
`Nielsen, Lars P., “Comparison of[ntranasal Corticosteroids andAnti-
`histamines inAllergic Rhinitis, AReView ofRandomized, Controlled
`Trials,” Am. J. Respir Med. 2003, Vol. 2, No. 1, Cover page, publish-
`ing page, pp. 55-65., ADIS International Limited.
`Nielsen, Lars Peter, et al., “Intranasal Corticosteroids for Allergic
`Rhinitis, Superior Relieff,” Drugs 2001, Vol. 61, No. 11, pp. 1563-
`1579, ADIS International Ltd.
`Di Lorenzo, G., et al., “Randomized Placebo-controlled Trial Com-
`paring fluticasone aqueous nasal spray in rnono-therapy, fluticasone
`plus cetirizine, fluticasone plus montelulcast and cetirizine plus
`montelukast for seasonal allergic rhinitis,” Clin. Exp. Allergy, 2004,
`vol. 34, pp. 259-267, Blackwell Publishing Ltd.
`Akerlund, Anders, et al., “Clinical trial design, nasal allergen chal-
`lenge models, and considerations of relevance to pediatrics, nasal
`polyposis, and different classes of medication,” J. Allergy Clin.
`Immu.nol., Mar. 2005, vol. 115, No. 3, pp. S460-S482.
`Howarth, P. H., “A comparison ofthe anti-inflammatoryproperties of
`intranasal corticosteroids and antihistamines in allergic rhinitis,”
`' Allergy 2000, vol. 62, pp. 6-1 1, Munksgaard 2000.
`Salib Rami Jean, et 23]., “Safety and Tolerability Profiles oflntranasal
`Antihistamines and Intranasal Corticosteroids in the Treatment of
`Allergic Rhinitis,” Drug Safety 2003, vol. 26, $10. 12, Cover page,
`publication page, pp. 863-893, ADIS Data Information BV.
`Simpson, Richard J., “Budesonide and terfenadine, separately and in
`combination, in the treatment of hay fever,” Annals ofAllergy, Dec.
`1994, Vol. 73, Cover page, publication page, pp. 497-502.
`Juniper, E F., et al., “Comparison of beclomethasone dipropionate
`aqueous nasal spray, astemizone, and the combination in the prophy-
`lactic treatment of ragweed pollen-induced rhinoco1:g‘unctivitis,”
`Journal ofAllergy and Clinical Immunology, Mar. 1989, vol. 83, No.
`3, Cover page, Publications page, pp. 627-633, American Academy
`ofAllergy and Irrirnimology, CV. Mosby Co.
`Barnes, M. L., et al., “Effects of levocetirizine as add-on therapy to
`fluticasone in seasonal allergic rhinitis,” Clinical and Experimental
`Allergy, Jan. 27, 2006, vol. 36, pp. 676-684, Blackwell Publishing
`Ltd.
`Applicants response to foreign communication—EP 0373 8280.1
`(EP Patent 1519731) , Sep. 5, 2010, 15 pages.
`File history ofAustralian Patent Application No. AU2003244799, 38
`pages.
`File history ofKorean Patent Application No. 10-2004-7020819, 89
`pages.
`File history of Mexican Patent Application No. PA/a/2004/01266
`(now Patent No. 265349), 86 pages.
`File history ofSouth African Patent Application No. 2005/0331 (now
`Patent No. 2005/0331), 18 pages.
`Applicants response to foreign communication——CA 2489427, Dec.
`20, 2010, 10 pages.
`Applicant Response to foreign communication EP Patent 15 19731,
`Aug. 11, 2011, 252 pages.
`Maus Exhibit B, Aug. 2011.
`Nielsen, 61 81-. “lntranasal corticosteroids for allergic rhinitis: supe-
`rior relief?” Drugs, 2001, vol. 61, No. 11, pp. 1535-1691.
`
`
`1211) dated L
`V
`Oilice Action (
`_l.7./37*'i,5:'..7v filed on
`7'1, .7100
`Applicants’ ;'e.spt:r:se dat
`‘ 3
`1.2/$74,523 filed on Jan.
`. ,
`. 1:;-111 datetl Jul. 6, F031 (3 jzwagesil,
`l'~1otice of
`‘on-m:;ponsiv~:-Ar"
`u.s.,~_-_,«:p1. No. 1.213-7-a W3 iii-ad. on
`-1, 2005».
`
`Ag-plic>1r1
`’
`..
`.
`-
`132;». 6, 1011 (:2? pages) in U..‘3.A;1§;l.N'o.
`.17./374 23 filed -an Earl. 21. 2009.
`‘Specter, Sheldon “ideal pl1ari11acr;ther'«'-v tin‘ all.ergi.r; ri:i.".il'is,“
`Allcrggr Cllnl.mmun"”'
`'01. 103, I‘?-.'3.“.1. 3,1,1:
`1. 3386-3387, 1.999.
`l:l!110}3£?,S6Da1‘
`lime
`corriplcte riiinitisxroirwz-1.” 6 pages,. Cipla.
`
`It.imite<i_ Mm
`, India, .004.
`lT’r<.:r1IW ‘ipacificank:-n Bulletin, »'wia:ei~?9 RC-5
`fill‘:-‘:31
`" 9.113, 2 pages, lilklfj ill»)? 0
`mclilcttzlawn Biillciin, Avi
`2C-(1-9.
`‘mar,
`- wages, F15/l4’_‘. Bio?’
`.lll.a1.l Patent Application ‘filo. Pl 03121255--Tl,
`
`
`
`
`
`
`‘.27
`
`Fileliietory ofCanadian "Fatah: , pplicarion. No. 2,489,427, 19 pager‘-,
`Dec. 2010.
`File history of Polisir Patent Application No. E‘-3'/31 «ii. :95 pages,
`May 2011.
`File history of Russian Patent Applic:11it.'«n ‘£1-lo.
`pages, Apr. 2009.
`
`;‘:‘3¢.‘.~i593 C2,, 65
`
`
`
`.»w.....a..«-1a.:.~.w.«.«.«».~na---~»~»~r-~»~*--t-rw......~... .-.-
`
`
`
`
`
`
`
`
`. . . . . .7-'»rJ»*~\~f«I»NV$5\S\Ah‘v‘JuPrrvv .A......................................
`ffiopy it
`‘iissro tmm“i‘i?ee ;=1as"im.
`
`
`
`
`.,.,.....................-.-...-.-.-vw...-H..x-.c :.v..v;..;.1..xxxat-tuwt-.—-i-tut-.-t-.-.-.u-.u.-_-.».-.u..w.-
`gge ilatataaseee on as.«'a4:ao-is
`
`
`-
`..
`....
`....
`...........................
`
`MED_DYM_00018030
`
`

`
`Case 1:14-cv-01453-LPS Document 43-2 Filed 10/22/15 Page 7 of 17 PageID #: 266
`Case 1:14—cv—01453—LPS Document 43-2 Filed 10/22/15 Page 7 of 17 Page|D #: 266
`
`
`
`{.75 8,168,620 B2
`
`Page 5
`
`.
`
`
`
`Salib, et al., “Safety and Tolerability Profiles of Intranasal
`Anihistaminese and Intranasal Corticosteroids in the Treatment of
`Allergic Rhinitis," Drug Safety; 2003; vol. 26, No. 12, pp. 829-911.
`Ofiiice Action dated Apr. 7, 201 1 (3 pages) fiom counterpart applica-
`tion, AU2009243420.
`Moreno-Vargas, et al., “Synthesis and gylcosidase inhibitory activi-
`ties of 5-(l',4‘-d.ideoxy-1‘,4‘-irnino-D~erythrosyl)—2-methyl-3-furoic
`acid (=5-[(3S,4R)-3,4-dihydroxypyrrolidin-2-yl]-2methylfi1ran-3-
`carboxylic acid) derivatives: new leads as
`selective alpha-L-
`fucosidase and beta-galactosidase inhibitors,” Helvetica Chimica
`Acta, vol. 86, pp. 1894-1913, 2003.
`Nathan, et al., “A once daily fluticasone proprionate aqueous nasal
`spray is an eflective treatment for seasonal allergic rhinitis,” Annals
`ofA1lergy, 1991, vol. 67, pp. 332-338.
`Nelson, Harold, S., et al., Fluticasone propionate-salmctcrol combi-
`nation provides more effective asthma control than low-dose inhaled
`corticosteroid plus rnontelukast, J. Allergy Clin. l.m.munol., vol. 106,
`No. 6, Dec. 2000, pp. 1088-1095.
`Ong, John T. H., et al., “Micellar solubilization oftimobesone acetate
`in aqueous and aqueous propylene glycol solutions of nonionic
`surfactants,” Pharmaceutical Resear-:;h, vol. 5, No. 11, 1988, pp.
`704-708.
`Ong, John T. H., et al., “Intrinsic potencies of novel thiol ester
`corticosteroids RS-85095 and RS-21314 as compared with
`clobetasol 17-propionate and fluocinonide,” Arch Dermatol, vol.
`125, Dec. 1989, pp. 1662-1665.
`Onrust, et al., “Mometasone furoate. a review of its intranasal use in
`allergic rhinitis,” Drugs, vol. 56, No. 4, Oct. 1998, pp. 725-745, vol.
`21.
`
`Phillips, G. H., et al., “Synthesis and structure activity relationships
`in a series ofanti-inflammatory corticosteroid analogues, halorncthyl
`and;rostane—17B-carbothioates and——17B-carboselenoates,” Jour-
`nal of Medicinal Chemistry, 1994, vol. 37, pp. 3717-3729.
`Product Information Flonase (Fluticasone proprionate) Nasal Spray
`50 mcg, 2004, pp. 1-13.
`Product Infomtation Rhinocort Aqua (budesonide) Nasal Spray 32
`meg, 2005, pp. 1-2.
`- Sakagami, et al., “Mucoadhexive EDP microspheres for powder
`inhalation—-their unique pharrnacokinetic-pharmacodynamic pro-
`files,” Respiratory Drug Delivery, vo1.VI, pp. 193-199, 1998.
`Sandham, et al., “Synthesis and biological properties of novel
`glucocorticoid androstene C-17 furoate esters,” Bioorganic &
`Medicinal Chemistry, 2004, vol. 12, pp. 5213-5224.
`Scadding, et al., “Clinical and physiological effects of fluticasone
`propionate aqueous nasal spray in the treatment ofperennial rhinitis,”
`Rhinology, 1991, Suppl. 11, pp. 37-43.
`Settipane, et al., “Triamcinolone acetonide aqueous nasal spray in
`patients with seasonal ragweed allergic rhinitis: aplacebo-controlled,
`double—bli.nd study,” Clin. Ther., 1995, vol. 17, No. 2, pp. 252-263.
`Shapiro, et al., “l7-esters and 17,21-diestcrs of 9-alpha, 1l-beta-
`dichlorocorticoids. Synthesis and anti-inflammatory activity," Ste-
`roids, Vol.9, No.2, pp. 143-156, 1967.
`Shapiro, et
`al., “Synthesis and structure-activity studies of
`corticosteroid 17-heterocyclic aromatic esters. 1. 9-alpha, ll-beta
`dichloro series,” Journal of Medicinal Chemistry, vol. 30, No. 6, pp.
`1068-1073, 1987.
`Shapiro, et al., “l7 heteroaroyl esters of corticosteroids 2. 11 beta
`hydroxy series,” Journal of Medicinal Chemistry, American Chemi-
`cal Society, Washington, US, vol. 30, No. 9, 1987, pp. 1581-1588.
`Smith, et al., “In vitro glucocorticoid receptor binding and transcrip-
`tional
`activiation
`by
`topically
`active
`glucocorticoids,”
`Aizneimettelforschung, 1998, 48(II)(9), pp. 956-959.
`Smith, N., et al., “Comparison ofthe electroosmotic flow profiles and
`selectivity
`of
`stationary
`phases
`used
`in
`capillary
`elect:roch.romatography,” Journal of Chromatography A., vol. 832,
`1999, pp. 41-54.
`Souness, et al., “Lmmunosuppressive and anti-inflammatory effects
`of cyclic AMP phosphodiesterase (PDE)
`type 4 inhibitors,”
`Imrnunophamiacology, 2000, vol. 47, Nos. 2/3, pp. 127-162.
`Stempel, et al., “Treatment of allergic rhinitis: an evidence-based
`evaluation of nasal corticosteroids versus nonsedating antihista-
`mines,” Am. J. Man. Care, 1998, vol. 4, pp. 89-96.
`
`Study No. 03DMWO62——“Pharmacokinetics of GW685698X and
`CC1 18781 (fiuticasone propionate) when co—administered by the
`intratracheal or intravenous route to the anaesthetised white pig,”
`2004.
`Study No. B30947~—“The Pharmacokinetics of GW685698X and
`CC118781
`following intratracheal
`co-administration to the
`anaesthetised white pig,” 2003.
`Szefler, Stanley J., et al., Chapter 21, “Glucocorticoids in severe
`asthma: mechanisms ofaction and route of administration,” Difiicult
`Asthma, pp. 371-375, Martin Dunitz Ltd., Informa Health Care,
`1999.
`
`Togashi, et al., 9-fluoro-11B, 17, 2l-t1'ihyrdroxy-16a-methy1-1,4-
`pregnadiene-3,
`20-dione
`21-
`cyclohexanecarboxylate
`17-cyclopropanecarboxylate (ST126); Oyo Yakuri, 2002, vol. 63,
`No. 5/6, pp. 61-77.
`Undern, et al., “Neural integration and allergic disease," J. Allergy
`Clin. I.mmunol., 2000, vol. 106, No. 5, pp. S213-S220.
`The United States Pharmacopoeia, 23rd Ed., US Pharmacopoeia
`Convention, Inc., Rockville MD, 1995, pp. 1843-1844, “Physical
`Tests/(941) X-Ray Diffraction.”
`Van As, eta1., “Once daily flluticasone propionate is as efiective for
`perennial
`allergic
`rhinitis
`as
`twice
`daily beclomethasone
`dipropionate,” J. Allergy Clin. l_mmunol., 1993, vol. 91, No. 6, pp